- Home
- IMNN vs NXTC Comparison
IMNN vs NXTC Comparison
Compare IMNN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- NXTC
- Stock Information
- Founded
- IMNN 1982
- NXTC 2015
- Country
- IMNN United States
- NXTC United States
- Employees
- IMNN N/A
- NXTC N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- NXTC Health Care
- Exchange
- IMNN Nasdaq
- NXTC Nasdaq
- Market Cap
- IMNN 12.1M
- NXTC 13.9M
- IPO Year
- IMNN 1985
- NXTC 2019
- Fundamental
- Price
- IMNN $0.77
- NXTC $0.48
- Analyst Decision
- IMNN Buy
- NXTC Strong Buy
- Analyst Count
- IMNN 2
- NXTC 2
- Target Price
- IMNN $14.00
- NXTC $3.50
- AVG Volume (30 Days)
- IMNN 5.4M
- NXTC 336.1K
- Earning Date
- IMNN 08-13-2025
- NXTC 07-31-2025
- Dividend Yield
- IMNN N/A
- NXTC N/A
- EPS Growth
- IMNN N/A
- NXTC N/A
- EPS
- IMNN N/A
- NXTC N/A
- Revenue
- IMNN N/A
- NXTC N/A
- Revenue This Year
- IMNN N/A
- NXTC N/A
- Revenue Next Year
- IMNN N/A
- NXTC N/A
- P/E Ratio
- IMNN N/A
- NXTC N/A
- Revenue Growth
- IMNN N/A
- NXTC N/A
- 52 Week Low
- IMNN $0.37
- NXTC $0.22
- 52 Week High
- IMNN $3.65
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- IMNN 40.14
- NXTC 44.82
- Support Level
- IMNN $0.93
- NXTC $0.45
- Resistance Level
- IMNN $1.03
- NXTC $0.51
- Average True Range (ATR)
- IMNN 0.18
- NXTC 0.07
- MACD
- IMNN -0.10
- NXTC -0.01
- Stochastic Oscillator
- IMNN 1.39
- NXTC 3.24
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.